NO311621B1 - Kryssbundne kopolymerer basert på polymerer inneholdende karboksylsyre, fremgangsmåte for fremstilling av disse,farmasöytisk preparat som inneholder kopolymerer, samt anvendelseav det farmasöytiske preparatet - Google Patents

Kryssbundne kopolymerer basert på polymerer inneholdende karboksylsyre, fremgangsmåte for fremstilling av disse,farmasöytisk preparat som inneholder kopolymerer, samt anvendelseav det farmasöytiske preparatet Download PDF

Info

Publication number: NO311621B1
Authority: NO; Norway
Prior art keywords: polycarboxylic; acid; copolymers; poly; cross
Prior art date: 1996-08-30

Application number

NO19990935A

Other languages

English (en)

Norwegian (no)

Other versions

NO990935D0 (no

NO990935L (no

Inventor

Nada El Matni

Dennis Labarre

Hatem Fessi

Original Assignee

Sod Conseils Rech Applic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-30

Filing date

1999-02-26

Publication date

2001-12-17

1999-02-26 Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic

1999-02-26 Publication of NO990935D0 publication Critical patent/NO990935D0/no

1999-04-15 Publication of NO990935L publication Critical patent/NO990935L/no

2001-12-17 Publication of NO311621B1 publication Critical patent/NO311621B1/no

Links

229920001577 copolymer Polymers 0.000 title claims abstract description 81
229920000642 polymer Polymers 0.000 title claims abstract description 43
238000000034 method Methods 0.000 title claims abstract description 25
238000002360 preparation method Methods 0.000 title claims description 11
230000008569 process Effects 0.000 title claims description 7
239000008194 pharmaceutical composition Substances 0.000 title abstract 3
150000001732 carboxylic acid derivatives Chemical class 0.000 title 1
229920001282 polysaccharide Polymers 0.000 claims abstract description 27
239000005017 polysaccharide Substances 0.000 claims abstract description 27
-1 poly(glutamic acid) Polymers 0.000 claims description 61
150000004804 polysaccharides Chemical class 0.000 claims description 26
239000004480 active ingredient Substances 0.000 claims description 22
239000003431 cross linking reagent Substances 0.000 claims description 19
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 13
229920001287 Chondroitin sulfate Polymers 0.000 claims description 13
239000012190 activator Substances 0.000 claims description 13
229940059329 chondroitin sulfate Drugs 0.000 claims description 13
239000000825 pharmaceutical preparation Substances 0.000 claims description 10
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 7
229920002674 hyaluronan Polymers 0.000 claims description 7
229960003160 hyaluronic acid Drugs 0.000 claims description 7
210000002429 large intestine Anatomy 0.000 claims description 7
239000004472 Lysine Substances 0.000 claims description 6
239000012736 aqueous medium Substances 0.000 claims description 6
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
229920000058 polyacrylate Polymers 0.000 claims description 6
229920002683 Glycosaminoglycan Polymers 0.000 claims description 5
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 5
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 5
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
229920002125 Sokalan® Polymers 0.000 claims description 5
235000001014 amino acid Nutrition 0.000 claims description 5
150000001413 amino acids Chemical class 0.000 claims description 5
229920000669 heparin Polymers 0.000 claims description 5
229960002897 heparin Drugs 0.000 claims description 5
229920000768 polyamine Polymers 0.000 claims description 5
150000001412 amines Chemical group 0.000 claims description 4
210000001072 colon Anatomy 0.000 claims description 4
150000004985 diamines Chemical group 0.000 claims description 4
230000002035 prolonged effect Effects 0.000 claims description 4
229920000045 Dermatan sulfate Polymers 0.000 claims description 3
229920002971 Heparan sulfate Polymers 0.000 claims description 3
229920000288 Keratan sulfate Polymers 0.000 claims description 3
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 3
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 3
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 3
229920000805 Polyaspartic acid Polymers 0.000 claims description 3
239000000783 alginic acid Substances 0.000 claims description 3
229920000615 alginic acid Polymers 0.000 claims description 3
235000010443 alginic acid Nutrition 0.000 claims description 3
229960001126 alginic acid Drugs 0.000 claims description 3
150000004781 alginic acids Chemical class 0.000 claims description 3
150000008064 anhydrides Chemical class 0.000 claims description 3
229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 claims description 3
150000001718 carbodiimides Chemical group 0.000 claims description 3
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 3
229940051593 dermatan sulfate Drugs 0.000 claims description 3
201000010099 disease Diseases 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 3
229960003104 ornithine Drugs 0.000 claims description 3
229920003175 pectinic acid Polymers 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
229920002643 polyglutamic acid Polymers 0.000 claims description 3
229920001444 polymaleic acid Polymers 0.000 claims description 3
125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
229920001661 Chitosan Polymers 0.000 claims description 2
108010039918 Polylysine Proteins 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
239000000227 bioadhesive Substances 0.000 claims description 2
QVYARBLCAHCSFJ-UHFFFAOYSA-N butane-1,1-diamine Chemical compound CCCC(N)N QVYARBLCAHCSFJ-UHFFFAOYSA-N 0.000 claims description 2
JMLPVHXESHXUSV-UHFFFAOYSA-N dodecane-1,1-diamine Chemical compound CCCCCCCCCCCC(N)N JMLPVHXESHXUSV-UHFFFAOYSA-N 0.000 claims description 2
IZKZIDXHCDIZKY-UHFFFAOYSA-N heptane-1,1-diamine Chemical compound CCCCCCC(N)N IZKZIDXHCDIZKY-UHFFFAOYSA-N 0.000 claims description 2
SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 claims description 2
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
229920001277 pectin Polymers 0.000 claims description 2
239000001814 pectin Substances 0.000 claims description 2
235000010987 pectin Nutrition 0.000 claims description 2
229960000292 pectin Drugs 0.000 claims description 2
229920000656 polylysine Polymers 0.000 claims description 2
229920002714 polyornithine Polymers 0.000 claims description 2
108010055896 polyornithine Proteins 0.000 claims description 2
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
125000003916 ethylene diamine group Chemical group 0.000 claims 1
239000001630 malic acid Substances 0.000 claims 1
235000011090 malic acid Nutrition 0.000 claims 1
230000007935 neutral effect Effects 0.000 claims 1
150000004676 glycans Chemical class 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 description 11
108090000790 Enzymes Proteins 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
230000015556 catabolic process Effects 0.000 description 10
239000000203 mixture Substances 0.000 description 10
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
239000000725 suspension Substances 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
238000006731 degradation reaction Methods 0.000 description 6
239000002244 precipitate Substances 0.000 description 6
102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 5
108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 5
BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 5
229920002845 Poly(methacrylic acid) Polymers 0.000 description 5
239000002609 medium Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
229960004909 aminosalicylic acid Drugs 0.000 description 4
239000000872 buffer Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000004132 cross linking Methods 0.000 description 4
238000011835 investigation Methods 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
230000000813 microbial effect Effects 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
239000012429 reaction media Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000000112 colonic effect Effects 0.000 description 3
150000002016 disaccharides Chemical class 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
235000018977 lysine Nutrition 0.000 description 3
239000011859 microparticle Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000008188 pellet Substances 0.000 description 3
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
XNPOFXIBHOVFFH-UHFFFAOYSA-N N-cyclohexyl-N'-(2-(4-morpholinyl)ethyl)carbodiimide Chemical compound C1CCCCC1N=C=NCCN1CCOCC1 XNPOFXIBHOVFFH-UHFFFAOYSA-N 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
238000011161 development Methods 0.000 description 2
239000012738 dissolution medium Substances 0.000 description 2
230000007515 enzymatic degradation Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
244000005706 microflora Species 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000013557 residual solvent Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
238000005063 solubilization Methods 0.000 description 2
230000007928 solubilization Effects 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
LPBHYOYZZIFCQT-UHFFFAOYSA-N 2-methylpropyl 2-(2-methylpropoxy)-2h-quinoline-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OCC(C)C)C(OCC(C)C)C=CC2=C1 LPBHYOYZZIFCQT-UHFFFAOYSA-N 0.000 description 1
PXSFFHCHRCZARW-UHFFFAOYSA-N 2-methylpropyl 2-ethoxy-2h-quinoline-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OCC(C)C)C(OCC)C=CC2=C1 PXSFFHCHRCZARW-UHFFFAOYSA-N 0.000 description 1
DBRHBGTVTSQIQK-UHFFFAOYSA-N 2-methylpropyl 2-methoxy-2h-quinoline-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OCC(C)C)C(OC)C=CC2=C1 DBRHBGTVTSQIQK-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
229920000877 Melamine resin Polymers 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000003905 agrochemical Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000003509 anti-fertility effect Effects 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940124575 antispasmodic agent Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000012829 chemotherapy agent Substances 0.000 description 1
AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
239000012154 double-distilled water Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229960004198 guanidine Drugs 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
229940091868 melamine Drugs 0.000 description 1
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
229960004963 mesalazine Drugs 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
229940126578 oral vaccine Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
229940063675 spermine Drugs 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
- C08F8/32—Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Polymers & Plastics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Materials Engineering (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polyesters Or Polycarbonates (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Compositions Of Macromolecular Compounds (AREA)
Graft Or Block Polymers (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

NO19990935A 1996-08-30 1999-02-26 Kryssbundne kopolymerer basert på polymerer inneholdende karboksylsyre, fremgangsmåte for fremstilling av disse,farmasöytisk preparat som inneholder kopolymerer, samt anvendelseav det farmasöytiske preparatet NO311621B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9610601A FR2752843B1 (fr)	1996-08-30	1996-08-30	Copolymeres reticules a base de polymeres polycarboxyliques et leur utilisation comme support de composition pharmaceutique
PCT/FR1997/001534 WO1998008897A1 (fr)	1996-08-30	1997-08-29	Copolymeres reticules a base de polymeres polycarboxyliques

Publications (3)

Publication Number	Publication Date
NO990935D0 NO990935D0 (no)	1999-02-26
NO990935L NO990935L (no)	1999-04-15
NO311621B1 true NO311621B1 (no)	2001-12-17

Family

ID=9495309

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19990935A NO311621B1 (no)	1996-08-30	1999-02-26	Kryssbundne kopolymerer basert på polymerer inneholdende karboksylsyre, fremgangsmåte for fremstilling av disse,farmasöytisk preparat som inneholder kopolymerer, samt anvendelseav det farmasöytiske preparatet

Country Status (20)

Country	Link
EP (1)	EP0922071B1 (da)
JP (1)	JP4162265B2 (da)
AT (1)	ATE208803T1 (da)
AU (1)	AU730566B2 (da)
CA (1)	CA2266645C (da)
CZ (1)	CZ296041B6 (da)
DE (1)	DE69708304T2 (da)
DK (1)	DK0922071T3 (da)
ES (1)	ES2167784T3 (da)
FR (1)	FR2752843B1 (da)
HU (1)	HUP9903745A3 (da)
IL (1)	IL128619A (da)
MY (1)	MY116595A (da)
NO (1)	NO311621B1 (da)
NZ (1)	NZ334301A (da)
PL (1)	PL193227B1 (da)
PT (1)	PT922071E (da)
RU (1)	RU2194055C2 (da)
WO (1)	WO1998008897A1 (da)
ZA (1)	ZA977671B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1303738B1 (it) *	1998-11-11	2001-02-23	Aquisitio S P A	Processo di reticolazione di polisaccaridi carbossilati.
IT1303735B1 (it) *	1998-11-11	2001-02-23	Falorni Italia Farmaceutici S	Acidi ialuronici reticolati e loro usi medici.
US6288043B1 (en) *	1999-06-18	2001-09-11	Orquest, Inc.	Injectable hyaluronate-sulfated polysaccharide conjugates
FR2799196B1 (fr) *	1999-10-04	2002-02-08	Sod Conseils Rech Applic	Copolymeres reticules a base de copolymeres polycarboxyliques non reticules
KR100378109B1 (ko) *	2000-10-24	2003-03-29	주식회사 메디프렉스	소수성 다중복합 헤파린 결합체, 그의 제조방법 및 용도
WO2005007714A1 (ja) *	2003-07-18	2005-01-27	Japan Exlan Company Limited	アミノ酸誘導体徐放性重合体、該重合体を含有する化粧料及び繊維構造物並びにそれらの製造法及び再生処理法
FR2873379B1 (fr) *	2004-07-23	2008-05-16	Jerome Asius	Procede de preparation d'acide hyaluronique reticule, acide hyaluronique reticule susceptible d'etre obtenu par ledit procede, implant contenant ledit acide hyaluronique reticule, et son utilisation
GB2423252B (en) *	2005-02-18	2007-10-17	Engelhard Lyon	Cross-linked polymer of carbohydrate, notably based on polysaccharides, and/or on oligosaccharides and/or on polyols
RU2292354C1 (ru) *	2005-09-09	2007-01-27	Институт синтетических полимерных материалов (ИСПМ) им. Н.С. Ениколопова РАН	Способ получения привитых сополимеров хитина или хитозана с синтетическими полимерами
CN101432311A (zh) *	2006-02-28	2009-05-13	诺维信生物聚合物公司	透明质酸衍生物
EP1942117A1 (en) *	2006-12-29	2008-07-09	Sigea S.R.L.	Derivatives of acid polysaccharides
WO2009047802A2 (en) *	2007-10-10	2009-04-16	Lupin Limited	Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof
JP5722217B2 (ja)	2008-09-02	2015-05-20	アラーガン・ホールディングス・フランス・ソシエテ・パール・アクシオン・サンプリフィエＡｌｌｅｒｇａｎＨｏｌｄｉｎｇｓＦｒａｎｃｅＳ．Ａ．Ｓ．	ヒアルロン酸および／またはその誘導体の糸、その作製方法、ならびにその使用
CZ302789B6 (cs) *	2009-11-25	2011-11-09	Zentiva, K. S.	Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
US20110172180A1 (en)	2010-01-13	2011-07-14	Allergan Industrie. Sas	Heat stable hyaluronic acid compositions for dermatological use
HUE030138T2 (en)	2010-03-22	2017-04-28	Allergan Inc	Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US20130096081A1 (en)	2011-06-03	2013-04-18	Allergan, Inc.	Dermal filler compositions
US9408797B2 (en)	2011-06-03	2016-08-09	Allergan, Inc.	Dermal filler compositions for fine line treatment
AU2012262047A1 (en)	2011-06-03	2014-01-16	Allergan, Inc.	Dermal filler compositions including antioxidants
US9393263B2 (en)	2011-06-03	2016-07-19	Allergan, Inc.	Dermal filler compositions including antioxidants
US9662422B2 (en)	2011-09-06	2017-05-30	Allergan, Inc.	Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US20130244943A1 (en)	2011-09-06	2013-09-19	Allergan, Inc.	Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
FR2997014B1 (fr) *	2012-10-24	2015-03-20	Teoxane	Composition sterile dermo-injectable
ITUD20130119A1 (it) *	2013-09-12	2015-03-13	Limacorporate Spa	Idrogel biocompatibile per uso biomedico o farmaceutico, polimero intermedio per realizzare detto idrogel biocompatibile e relativo metodo di realizzazione
ES2811269T3 (es)	2014-01-31	2021-03-11	Seikagaku Kogyo Co Ltd	Agente de reticulación de diamina, cuerpo reticulado de polisacárido ácido y material médico
WO2016051219A1 (en)	2014-09-30	2016-04-07	Allergan Industrie, Sas	Stable hydrogel compositions including additives
EP3653232A1 (en)	2015-02-13	2020-05-20	Allergan Industrie, SAS	Implants for sculpting, augmenting or correcting facial features such as the chin
EP3386551A4 (en) *	2015-12-11	2018-10-24	The General Hospital Corporation	Dextran nanoparticles for macrophage specific imaging and therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4026851A (en) *	1975-08-13	1977-05-31	E. I. Du Pont De Nemours And Company	Acrylate polymers cured with diamines in the presence of an acid catalyst
US4026581A (en) *	1975-11-13	1977-05-31	Lacrex Brevetti S.A.	Releasable coupling
US4663050A (en) *	1982-01-18	1987-05-05	Standard Oil Company	Semipermeable membranes prepared from polymers containing adjacent, pendent carboxy groups
US4937270A (en) *	1987-09-18	1990-06-26	Genzyme Corporation	Water insoluble derivatives of hyaluronic acid
US5017229A (en) *	1990-06-25	1991-05-21	Genzyme Corporation	Water insoluble derivatives of hyaluronic acid
DE3809764A1 (de) *	1988-03-23	1989-10-05	Knoll Ag	Mischung aus alginaten und polyacrylaten und deren verwendung
HU210497B (en) *	1990-05-04	1995-04-28	Perio Prod Ltd	Process for production of modified pectin

1996
- 1996-08-30 FR FR9610601A patent/FR2752843B1/fr not_active Expired - Fee Related
1997
- 1997-08-26 ZA ZA9707671A patent/ZA977671B/xx unknown
- 1997-08-29 CZ CZ1999606A patent/CZ296041B6/cs not_active IP Right Cessation
- 1997-08-29 RU RU99106546/04A patent/RU2194055C2/ru not_active IP Right Cessation
- 1997-08-29 AU AU41215/97A patent/AU730566B2/en not_active Ceased
- 1997-08-29 WO PCT/FR1997/001534 patent/WO1998008897A1/fr not_active Ceased
- 1997-08-29 PT PT97938958T patent/PT922071E/pt unknown
- 1997-08-29 IL IL12861997A patent/IL128619A/en not_active IP Right Cessation
- 1997-08-29 DE DE69708304T patent/DE69708304T2/de not_active Expired - Lifetime
- 1997-08-29 CA CA002266645A patent/CA2266645C/fr not_active Expired - Fee Related
- 1997-08-29 ES ES97938958T patent/ES2167784T3/es not_active Expired - Lifetime
- 1997-08-29 EP EP97938958A patent/EP0922071B1/fr not_active Expired - Lifetime
- 1997-08-29 AT AT97938958T patent/ATE208803T1/de not_active IP Right Cessation
- 1997-08-29 HU HU9903745A patent/HUP9903745A3/hu unknown
- 1997-08-29 PL PL331848A patent/PL193227B1/pl not_active IP Right Cessation
- 1997-08-29 JP JP51134298A patent/JP4162265B2/ja not_active Expired - Fee Related
- 1997-08-29 DK DK97938958T patent/DK0922071T3/da active
- 1997-08-29 NZ NZ334301A patent/NZ334301A/en unknown
- 1997-08-30 MY MYPI97004035A patent/MY116595A/en unknown
1999
- 1999-02-26 NO NO19990935A patent/NO311621B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
PT922071E (pt)	2002-05-31
NZ334301A (en)	2000-06-23
FR2752843A1 (fr)	1998-03-06
NO990935D0 (no)	1999-02-26
WO1998008897A1 (fr)	1998-03-05
PL331848A1 (en)	1999-08-16
JP2001501228A (ja)	2001-01-30
DK0922071T3 (da)	2002-03-11
HUP9903745A3 (en)	2001-03-28
ZA977671B (en)	1998-02-23
AU4121597A (en)	1998-03-19
CA2266645C (fr)	2008-03-18
ES2167784T3 (es)	2002-05-16
NO990935L (no)	1999-04-15
MY116595A (en)	2004-02-28
IL128619A (en)	2004-02-19
EP0922071B1 (fr)	2001-11-14
DE69708304T2 (de)	2002-07-25
CZ60699A3 (cs)	2000-06-14
PL193227B1 (pl)	2007-01-31
DE69708304D1 (de)	2001-12-20
CZ296041B6 (cs)	2005-12-14
CA2266645A1 (fr)	1998-03-05
ATE208803T1 (de)	2001-11-15
RU2194055C2 (ru)	2002-12-10
AU730566B2 (en)	2001-03-08
HUP9903745A2 (hu)	2000-03-28
EP0922071A1 (fr)	1999-06-16
JP4162265B2 (ja)	2008-10-08
FR2752843B1 (fr)	1998-10-16
IL128619A0 (en)	2000-01-31

Legal Events

Date	Code	Title	Description
2011-04-04	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
AU730566B2 (en)	2001-03-08	Cross-linked copolymers based on polycarboxylic polymers
US6229009B1 (en)	2001-05-08	Polycarboxylic based cross-linked copolymers
US12540219B2 (en)	2026-02-03	Method for deacetylation of biopolymers
JP4745826B2 (ja)	2011-08-10	架橋多糖微粒子およびその製造方法
JP3094074B2 (ja)	2000-10-03	多糖ゲル組成物
CN112041378B (zh)	2024-02-09	可注射凝胶产品
Shukla et al.	2018	Applications of tamarind seeds polysaccharide-based copolymers in controlled drug delivery: An overview
RU99123632A (ru)	2001-09-20	Сшитые кристаллы протеина с контролируемым растворением
JPH11507679A (ja)	1999-07-06	水溶性ポリマーの粒子の水性分散液の製造法および得られた粒子
JP2001520986A (ja)	2001-11-06	放出制御処方
US9285360B2 (en)	2016-03-15	Silylated biomolecules
Varshousaz et al.	2005	Effect of citric acid as cross-linking agent on insulin loaded chitosan microspheres
JP2003522255A (ja)	2003-07-22	ニ官能ｌ−アミノ酸又はｌ−アミノエステル又はそれらの混合物と架橋したヒアルロン酸のゲル
US20070077305A1 (en)	2007-04-05	Biocompatible polymeric matrix and preparation thereof
JP2009215220A (ja)	2009-09-24	マイクロカプセル及びその製造方法
US7014845B1 (en)	2006-03-21	Crosslinked copolymers based on non-crosslinked polycarboxylic copolymers
HU187152B (en)	1985-11-28	Process for the immobilization of cyclodextrine glycoziltransferaze enzyme
JP2002527376A (ja)	2002-08-27	活性物質非経口投与用組成物
US20040171580A1 (en)	2004-09-02	Regioselectively reticulated polysaccharides
Sakeer	2017	Starch derivatives as carriers for bioactive agents
Patel et al.	2014	Stability of proteins and peptides in calcium alginate nanoparticles: a review
JPS5930721B2 (ja)	1984-07-28	β−１，３−グルカン誘導体